Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2024-212101

Published: 2024

Journal Articles

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2024-212215

Published: 2024

Journal Articles

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Ehsan Malek, Kimberly Crasti, Grant Schofield, Shernan G. Holtan, Megan M Herr, Marco Davila, You-Wen Qian, Brian Betts, Mackenzie Lieberman, Jason Tong, Colin Chavel, Kelvin P. Lee, Scott Olejniczak

Blood (2024) 144 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2024-198255

Published: 2024

Journal Articles

Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy

Taylor K Mandeville, Cory Mavis, Juan Gu, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 6845.

https://doi.org/10.1182/blood-2023-191051

Published: 2023

Journal Articles

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Taylor Mandeville, Cory Mavis, Juan Gu, Noah Lemoine, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 7398–7399.

https://doi.org/10.1182/blood-2022-170436

Published: 2022

Journal Articles

Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Taylor K Mandeville, Cory Mavis, Juan Gu, Scott Olejniczak, Gyorgy Paragh, Prasenjit Dey, Francisco J. Hernandez-Ilizaliturri

Blood (2021) 138 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2021-154128

Published: 2021

Journal Articles

Rituximab Resistance Is Associated with Global Downregulation of CD20 and CD54 In B-Cell Lymphoma Cells: Implication of CD20 Signaling on CD54

Ping-Chiao Tsai, Peter Dvorak, Naveen Bangia, Scott Olejniczak, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2010) 116 (21): 5077.

https://doi.org/10.1182/blood.V116.21.5077.5077

Published: 2010

Journal Articles

The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity

Ping-Chiao Tsai, Naveen Bangia, Scott Olejniczak, Francisco J. Hernandez-Ilizaliturri, Myron Czuczman

Blood (2008) 112 (11): 2607.

https://doi.org/10.1182/blood.V112.11.2607.2607

Published: 2008

Journal Articles

CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders

Sapna Khubchandani, MD, Terry Mashtare, MS, Mohammad Muhsin Chisti, MD, Gregory Wilding, Scott Olejniczak, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 5312.

https://doi.org/10.1182/blood.V112.11.5312.5312

Published: 2008

Journal Articles

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.

Francisco J. Hernandez-Ilizaliturri, MD, Arshad Iqbal, MS, Naheed Alam, MD, Seema Bhat, MD, Scott Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2006) 108 (11): 2523.

https://doi.org/10.1182/blood.V108.11.2523.2523

Published: 2006

Journal Articles

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas.

Francisco J. Hernandez-Ilizaliturri, MD, Seema Bhat, MD, Arshad Iqbal, MS, Scott Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2006) 108 (11): 2502.

https://doi.org/10.1182/blood.V108.11.2502.2502

Published: 2006

Journal Articles

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Structural Changes in the Internal Domain of CD20 Regulated at the Post-Transcriptional Level.

Myron S. Czuczman, MD, Scott Olejniczak, BS, Aruna C. Gowda, MD, Petr Starostik, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2004) 104 (11): 2280.

https://doi.org/10.1182/blood.V104.11.2280.2280

Published: 2004

NARROW

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Rituximab Resistance Is Associated with Global Downregulation of CD20 and CD54 In B-Cell Lymphoma Cells: Implication of CD20 Signaling on CD54

The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity

CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas.

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Structural Changes in the Internal Domain of CD20 Regulated at the Post-Transcriptional Level.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only